These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15864228)

  • 81. Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints.
    Capra WB
    Control Clin Trials; 2004 Apr; 25(2):168-77. PubMed ID: 15020035
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.
    Patel MR; Granger CB
    Drugs Today (Barc); 2005 Mar; 41(3):165-70. PubMed ID: 15883613
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Patients at risk or patients at no risk after uncomplicated myocardial infarction? The COSTAMI project].
    Desideri A
    Cardiologia; 1998 Dec; 43(12):1323-6. PubMed ID: 9988940
    [No Abstract]   [Full Text] [Related]  

  • 84. Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions.
    Lin GM
    Cardiovasc Hematol Disord Drug Targets; 2011; 11(2):97-101. PubMed ID: 22044037
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention?
    Beranek JT
    Circulation; 2004 Apr; 109(16):e195-6; author reply e195-6. PubMed ID: 15117866
    [No Abstract]   [Full Text] [Related]  

  • 86. Defining "appropriateness": the devil is in the definition.
    Redberg RF
    Arch Intern Med; 2011 Oct; 171(18):1673-4. PubMed ID: 21987198
    [No Abstract]   [Full Text] [Related]  

  • 87. The INTERHEART study: intersection between behavioral and general medicine.
    Sheps DS; Frasure-Smith N; Freedland KE; Carney RM
    Psychosom Med; 2004; 66(6):797-8. PubMed ID: 15564341
    [No Abstract]   [Full Text] [Related]  

  • 88. Is the placebo powerless?
    Kupers R
    N Engl J Med; 2001 Oct; 345(17):1278; author reply 1278-9. PubMed ID: 11680457
    [No Abstract]   [Full Text] [Related]  

  • 89. Extending the useful life of clinical trials.
    Cowper PA; Peterson ED
    Am Heart J; 2000 Oct; 140(4):552-3. PubMed ID: 11011326
    [No Abstract]   [Full Text] [Related]  

  • 90. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: 'Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?' (Thromb Haemost 2012; 108.3).
    Verheugt FW
    Thromb Haemost; 2012 Sep; 108(3):410-1. PubMed ID: 22836950
    [No Abstract]   [Full Text] [Related]  

  • 91. Nuclear cardiology in randomized multicenter clinical trials.
    Beller GA
    J Nucl Cardiol; 2004; 11(3):235-6. PubMed ID: 15173767
    [No Abstract]   [Full Text] [Related]  

  • 92. [Typically German?].
    Silber S
    Dtsch Med Wochenschr; 2004 Apr; 129(15):838. PubMed ID: 15054692
    [No Abstract]   [Full Text] [Related]  

  • 93. To open or not to open: that remains the question.
    Mathew V; Gersh BJ
    Eur Heart J; 2004 Dec; 25(24):2177-9. PubMed ID: 15589631
    [No Abstract]   [Full Text] [Related]  

  • 94. Effect of GL enzyme (a highly purified form of hyaluronidase) on mortality after myocardial infarction.
    Flint EJ; De Giovanni J; Cadigan PJ; Lamb P; Pentecost BL
    Lancet; 1982 Apr; 1(8277):871-4. PubMed ID: 6122099
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Targeting p-selectin during coronary interventions: the elusive link between inflammation and platelets to prevent myocardial damage.
    Alfonso F; Angiolillo DJ
    J Am Coll Cardiol; 2013 May; 61(20):2056-9. PubMed ID: 23500231
    [No Abstract]   [Full Text] [Related]  

  • 96. Is our method of obtaining consent appropriate for randomised controlled trials in acute myocardial infarction?
    Williams BF; French JK; White HD
    N Z Med J; 1997 Aug; 110(1049):298-9. PubMed ID: 9293286
    [No Abstract]   [Full Text] [Related]  

  • 97. [Clinical trials. When and why: the principle of randomization and double-blind method].
    de Giuli F
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):973-5. PubMed ID: 12497860
    [No Abstract]   [Full Text] [Related]  

  • 98. In the pipeline..
    Harv Heart Lett; 2000 Mar; 10(7):7-8. PubMed ID: 10799150
    [No Abstract]   [Full Text] [Related]  

  • 99. Vitamin E-gads.
    Gorman C
    Time; 2005 Mar; 165(13):73. PubMed ID: 15806987
    [No Abstract]   [Full Text] [Related]  

  • 100. Dutch probiotics study is criticised for its "design, approval, and conduct".
    Sheldon T
    BMJ; 2010 Jan; 340():c77. PubMed ID: 20053835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.